NPC(SH:600713)2018-08-17 16:00Financial Performance - The company's operating revenue for the first half of 2018 was CNY 14,767,193,249.31, representing a 9.45% increase compared to CNY 13,492,497,878.58 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was CNY 138,797,783.02, up 23.52% from CNY 112,367,652.84 year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 141,030,000.62, a significant increase of 44.76% compared to CNY 97,421,343.57 in the previous year[20]. - Basic earnings per share for the first half of 2018 were CNY 0.137, a 9.60% increase from CNY 0.125 in the same period last year[22]. - The company reported a total comprehensive income of CNY 230,774,339.82 for the first half of 2018, compared to CNY 147,459,376.92 in the same period of 2017, reflecting a growth of 56.38%[145]. - The net profit for the first half of 2018 reached CNY 173,913,263.91, representing a 18.43% increase from CNY 146,856,495.62 in the previous year[145]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 18,039,890,651.65, reflecting a 13.28% increase from CNY 15,925,206,287.67 at the end of the previous year[21]. - The total liabilities of the company were CNY 13,826,263,134.53, up from CNY 12,738,684,465.19, reflecting an increase of approximately 8.5%[138]. - The equity attributable to the parent company reached CNY 3,797,795,223.79, compared to CNY 2,777,721,431.60 at the beginning of the period, indicating a growth of about 36.6%[139]. - The total assets of the company at the end of the period were 3,257.37 million RMB, showing growth from the previous total[165]. Cash Flow - The net cash flow from operating activities was negative at CNY -711,804,874.87, slightly improved from CNY -723,221,515.15 in the same period last year[20]. - The cash flow from operating activities showed a net outflow of ¥711,804,874.87, slightly improved from a net outflow of ¥723,221,515.15 in the previous period[150]. - The cash inflow from financing activities was ¥8,951,730,457.47, significantly higher than ¥5,120,000,000.00 in the previous period, representing a growth of 75.5%[151]. - The overall financial position improved with a net increase in cash and cash equivalents of 389,385,274.30 RMB, compared to 225,079,504.23 RMB in the previous period[155]. Investments and R&D - Research and development expenses increased significantly by 113.42% to ¥7,725,732.33 from ¥3,619,990.38, indicating a stronger focus on innovation[63]. - The company is investing 200 million RMB in R&D for new drug development, focusing on oncology and chronic diseases, with expected completion by the end of 2019[93]. - The company made a total investment of ¥5,998.61 million during the reporting period, marking a 100% increase compared to the previous year[69]. Market Position and Strategy - The company serves over 46,000 customers and has established good relationships with the top 50 pharmaceutical suppliers[27]. - The company is ranked eighth in the domestic pharmaceutical distribution industry by business scale[27]. - The pharmaceutical distribution industry is expected to see increased competition and consolidation, with smaller companies struggling to survive[36]. - The company aims to leverage new technologies such as big data and cloud computing to improve its supply chain services[39]. - The company is focusing on expanding its "Internet+" business model to enhance its e-commerce capabilities[31]. Shareholder Information - The company completed a non-public offering of shares, increasing the total share capital to 1,041,611,244 shares from 897,425,598 shares at the end of the previous year[22]. - The top shareholder, Nanjing Pharmaceutical Group, holds 241,811,214 shares, representing 23.22% of the total shares[123]. - The company issued a total of 15 million yuan in short-term financing bonds across three phases in July and August 2018, with each issuance amounting to 5 million yuan[86]. Governance and Compliance - The company has committed to maintaining operational independence and avoiding conflicts of interest with its controlling shareholders[90]. - The company appointed KPMG Huazhen as the financial audit and internal control audit institution for the fiscal year 2018, with a total audit fee not exceeding RMB 3.3 million[95]. - There were no significant lawsuits or arbitration matters during the reporting period[95]. Operational Efficiency - The company’s inventory turnover rate remains high compared to peers, indicating strong operational efficiency[45]. - The company has a comprehensive logistics service that includes centralized procurement, regional storage, and unified distribution[32]. - The company is actively exploring new service models and business innovations to cultivate new profit growth points[59].